1 | Natalizumab | Bg00002 (natalizumab) [19] Bg00002 (natalizumab); Bg00002-e (natalizumab high titer); Bg0002 (natalizumab); Dosing interruption of natalizumab; Natalizumab; Natalizumab (bg00002); Natalizumab (ntz); Natalizumab (tysabri); Natalizumab for iv infusion; Natalizumab for subcutaneous injection; Natalizumab injection [tysabri]; Natalizumab iv; Natalizumab sc; Natalizumab treatment; Other: natalizumab; Other: natalizumab discontinuation; Personalized extended interval dosing of natalizumab; Tysabri ® (natalizumab); Tysabri® (natalizumab); | [1] D06886 D06886 💬 |
[1] ITGA4 💬 |
Arrhythmogenic right ventricular cardiomyopathy [14] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
013 [6] 13, 15, 25, 46, 63, 96 💬 |